CLINICAL_TRIALS
trial_result
· 2011-03-10
Clinical Trial Update: Trial of 6% HES130/0.4 [Phase 3]
Summary
A Phase 3 trial evaluating 6% hydroxyethyl starch 130/0.4 for hypovolemia and hemorrhage has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Fresenius Kabi Japan | Conditions: Hypovolemia, Hemorrhage | Phase 3 | Status: COMPLETED